Last reviewed · How we verify
Naftifine Hydrochloride Cream 2%
Naftifine Hydrochloride Cream 2% is a Allylamine antifungal Small molecule drug developed by Sun Pharmaceutical Industries, Inc.. It is currently in Phase 3 development for Tinea pedis (athlete's foot), Tinea cruris (jock itch), Tinea corporis (ringworm). Also known as: Naftifine, Naftifine hcl.
Naftifine is a fungistatic agent that inhibits fungal sterol synthesis by blocking squalene epoxidase, disrupting the fungal cell membrane.
Naftifine is a fungistatic agent that inhibits fungal sterol synthesis by blocking squalene epoxidase, disrupting the fungal cell membrane. Used for Tinea pedis (athlete's foot), Tinea cruris (jock itch), Tinea corporis (ringworm).
At a glance
| Generic name | Naftifine Hydrochloride Cream 2% |
|---|---|
| Also known as | Naftifine, Naftifine hcl |
| Sponsor | Sun Pharmaceutical Industries, Inc. |
| Drug class | Allylamine antifungal |
| Target | Squalene epoxidase |
| Modality | Small molecule |
| Therapeutic area | Dermatology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Naftifine hydrochloride is an allylamine antifungal that works by inhibiting squalene epoxidase, a key enzyme in the ergosterol synthesis pathway of fungi. This inhibition disrupts the integrity of the fungal cell membrane, leading to fungistatic activity (stopping fungal growth). It is applied topically as a cream for dermatophyte and other fungal skin infections.
Approved indications
- Tinea pedis (athlete's foot)
- Tinea cruris (jock itch)
- Tinea corporis (ringworm)
- Other dermatophyte infections
Common side effects
- Local irritation (burning, stinging, erythema)
- Pruritus
- Dryness
Key clinical trials
- Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis (PHASE1)
- BE Study of Naftifine HCL (PHASE3)
- Evaluate the Safety and Efficacy of Naftifine Hydrochloride Cream 2% and Naftin® Cream 2% in Patients With Tinea Pedis (PHASE1)
- Pediatric Subjects With Tinea Corporis (PHASE4)
- An Open Label Pharmacokinetic Study of Naftin for Tinea Corporis (PHASE4)
- Evaluate the Clinical Equivalence of Two Naftifine HCl 1% Creams in Patients With Interdigital Tinea Pedis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Naftifine Hydrochloride Cream 2% CI brief — competitive landscape report
- Naftifine Hydrochloride Cream 2% updates RSS · CI watch RSS
- Sun Pharmaceutical Industries, Inc. portfolio CI
Frequently asked questions about Naftifine Hydrochloride Cream 2%
What is Naftifine Hydrochloride Cream 2%?
How does Naftifine Hydrochloride Cream 2% work?
What is Naftifine Hydrochloride Cream 2% used for?
Who makes Naftifine Hydrochloride Cream 2%?
Is Naftifine Hydrochloride Cream 2% also known as anything else?
What drug class is Naftifine Hydrochloride Cream 2% in?
What development phase is Naftifine Hydrochloride Cream 2% in?
What are the side effects of Naftifine Hydrochloride Cream 2%?
What does Naftifine Hydrochloride Cream 2% target?
Related
- Drug class: All Allylamine antifungal drugs
- Target: All drugs targeting Squalene epoxidase
- Manufacturer: Sun Pharmaceutical Industries, Inc. — full pipeline
- Therapeutic area: All drugs in Dermatology / Infectious Disease
- Indication: Drugs for Tinea pedis (athlete's foot)
- Indication: Drugs for Tinea cruris (jock itch)
- Indication: Drugs for Tinea corporis (ringworm)
- Also known as: Naftifine, Naftifine hcl
- Compare: Naftifine Hydrochloride Cream 2% vs similar drugs
- Pricing: Naftifine Hydrochloride Cream 2% cost, discount & access